The 2016 Vaccine Development Pipeline: A special issue from the World Health Organization Product Development for Vaccine Advisory Committee (PDVAC)  by Giersing, Birgitte K. et al.
PT
W
A
d
m
l
i
t
m
i
h
i
m
p
t
s
d
i
s
n
t
p
m
I
v
w
d
m
r
r
c
t
i
m
a
v
p
a
t
M
h
0Vaccine 34 (2016) 2863–2864
Contents lists available at ScienceDirect
Vaccine
j our na l ho me page: www.elsev ier .com/ locate /vacc ine
reface
he  2016  Vaccine  Development  Pipeline:  A  special  issue  from  the
orld  Health  Organization  Product  Development  for  Vaccine
dvisory  Committee  (PDVAC)Infectious diseases are the leading cause of death among chil-
ren and adolescents globally, and one of the primary causes of
ortality in adults. Most of these deaths disproportionately burden
ow- and middle-income countries (LMICs) and are attributable to
nfectious diseases that include diarrheal illnesses, lower respira-
ory infections, human immunodeﬁciency virus, tuberculosis and
alaria. Socio-economic gains have translated into improvements
n sanitation systems, clean water supplies, early diagnosis and
ealthcare accessibility and delivery, with consequent reductions
n infectious disease incidence and mortality. However, for the
ajority of the world’s population, large scale advancements in
ublic health infrastructure are still far off. For these communi-
ies, high-impact, low-cost public health interventions remain a key
trategy for driving down the preventable infectious disease inci-
ence and mortality. Principal among these cost-effective measures
s immunization; however, some vaccines are unavailable, inacces-
ible, and/or unaffordable for the populations most in need. Global
ational immunization programmes, partially ﬁnanced through
he Gavi vaccine alliance, are estimated to save 2–3 million lives
er year with the existing vaccines – and these could be even
ore impactful if greater levels of coverage could be achieved.
nvestments into the research, development and deployment of
accines and delivery technologies against the deadliest and most
idespread pathogens are, therefore, likely to yield considerable
ividends in global health.
There are approximately 600 vaccine candidates in develop-
ent against an estimated 110 pathogens [1]. Considering the
esource constraints in vaccine development, there is a need to
ationally identify the approaches that are most likely to suc-
eed and then prioritize among these candidates. Additionally, as
he routine immunization schedule expands, it becomes increas-
ngly important to have strong, evidence-based justiﬁcations for
 Disclaimer:  Birgitte Giersing, Vasee Moorthy and Jean-Marie Okwo-Bele are staff
embers of the World Health Organization. David C. Kaslow is an employee of PATH,
n international nonproﬁt organization. The authors alone are responsible for the
iews expressed in this article and they do not necessarily express the decisions,
olicy or views of the World Health Organization. The opinions expressed herein
re also those of the authors and should not be construed as ofﬁcial or representing
he views of the US Department of Defense or the Department of the Army (Kayvon
odjarrad) or PATH (David C. Kaslow).
ttp://dx.doi.org/10.1016/j.vaccine.2016.04.041
264-410X/© 2016 World Health Organization; licensee Elsevier Ltd. This is an open acceinvesting in the development of new vaccines with a high likeli-
hood of success. Just as innovation should be applied to the domain
of vaccines in the development pipeline, there is room for improve-
ment of some licensed vaccines with respect to cost-effectiveness
and coverage in order to maximize their public health impact.
This special issue, however, focuses its review on the research and
development (R&D) pipeline of vaccines against 25 pathogens for
which no licensed vaccines currently exists but for which there is
high public health importance, as identiﬁed by the World Health
Organization (WHO) Product Development for Vaccines Advisory
Committee (PDVAC). PDVAC is a body of independent experts that
was established in 2014 to guide WHO  and the vaccine develop-
ment community along the pathway toward the goal of licensure
and deployment in countries of highest disease burden. As such,
PDVAC’s remit is to advise on the acceleration of vaccine candidates
at Phase 2 of clinical evaluation or earlier and report its proceedings
from its meetings to the WHO’s principal committee on immu-
nization policy recommendations: the Strategic Advisory Group of
Experts on Immunization (SAGE).
PDVAC also has a contributory role within the framework of
the R&D Blueprint at WHO  for R&D preparedness and emer-
gency research response in the emerging pathogen area. When
WHO declares a Public Health Emergency of International Concern
(PHEIC), PDVAC may  be tasked with forming a working group to
facilitate development of guidance tools for the vaccine develop-
ment community in the context of the emergency. For example, as
this issue goes to press, a PDVAC Working Group is developing a
WHO  Zika vaccine Target Product Proﬁle [2].
The landscape analyses in this issue are intended as structured
overviews of the key considerations for vaccine development, not
as exhaustive literature reviews. They are authored by indepen-
dent subject matter experts in each ﬁeld and follow a template set
forth by the PDVAC committee. Each report summarizes the biolog-
ical evidence for a vaccine’s feasibility, the data on proof-of-concept
studies, existing knowledge gaps, the technical and regulatory hur-
dles to vaccine licensure, and the prospects for donor funding and
procurement of the product. The compendium of pathogens high-
lighted in this issue was  agreed upon by PDVAC in 2015 [3]. Each
year, pathogens and diseases to be reviewed is modiﬁed to incorpo-
rate new areas where vaccine development activity is progressing,
and in 2016, Zika will be discussed. In this way, PDVAC remains
ss article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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t the cutting edge of product development issues, with oversight
cross a broad spectrum of R&D activity, ensuring that its contrib-
tions are relevant and impactful to vaccine developers, regulators,
onors and policy makers.
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